Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8593083 | 0.83 | ALDH1A1 (0.34) | ALDH1A1CYP2C9LMNACYP3A4CYP2C19 | |
| SCHEMBL26477096 | 0.74 | PAOX (0.34) | — | |
| SCHEMBL7563469 | 0.72 | LMNA (0.33) | CYP2C9LMNA | |
| SCHEMBL6960808 | 0.71 | LMNA (0.31) | CYP2C9LMNA | |
| SCHEMBL8197883 | 0.69 | LMNA (0.32) | CYP2C9LMNA | |
| SCHEMBL8459306 | 0.69 | CYP2C9 (0.32) | CYP2C9LMNACYP3A4CYP2C19ALOX15 | |
| SCHEMBL3385057 | 0.69 | TSHR (0.40) | ALDH1A1CYP2C9LMNACYP3A4CYP2C19 | |
| SCHEMBL7517029 | 0.68 | CYP2C9 (0.41) | ALDH1A1CYP2C9LMNACYP3A4CYP2C19 | |
| SCHEMBL16065315 | 0.68 | — | — | |
| SCHEMBL4252207 | 0.68 | CYP2C9 (0.41) | ALDH1A1CYP2C9LMNACYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1249448-B1 | 3-Acetyl-n-substituted-3-aminomethyltetrahydroguran-2-one derivative and process therefor | DAICEL CHEM (JP) | 2010-12-15 | — | — | EP | claimed |
| US-6498258-B2 | SUCH AS 3-ACETYL-N,N-DIBENZYL-3-AMINOMETHYLTETRAHYDROFURAN-2-ONE FORMED VIA AMINOMETHYLATION WITH FORMALDEHYDE AND PRIMARY/SECONDARY AMINE; DEACYLATION; HYDROGENOLYSIS | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2002-12-24 | — | — | US | claimed |
| US-20020151727-A1 | 3-ACETYL-N-SUBSTITUTED-3-AMINOMETHYLTETRAHYDROFURAN-2-ONE DERIVATIVE AND PRODUCTION PROCESS THEREFOR | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2002-10-17 | — | — | US | claimed |
| EP-1249448-A1 | 3-Acetyl-n-substituted-3-aminomethyltetrahydroguran-2-one derivative and process therefor | Daicel Chemical Industries, Ltd. (JP) | 2002-10-16 | — | — | EP | claimed |
| EP-1249448-B1 | 3-Acetyl-n-substituted-3-aminomethyltetrahydroguran-2-one derivative and process therefor | DAICEL CHEM (JP) | 2010-12-15 | — | — | EP | disclosed |
| US-6498258-B2 | SUCH AS 3-ACETYL-N,N-DIBENZYL-3-AMINOMETHYLTETRAHYDROFURAN-2-ONE FORMED VIA AMINOMETHYLATION WITH FORMALDEHYDE AND PRIMARY/SECONDARY AMINE; DEACYLATION; HYDROGENOLYSIS | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2002-12-24 | — | — | US | disclosed |
| US-20020151727-A1 | 3-ACETYL-N-SUBSTITUTED-3-AMINOMETHYLTETRAHYDROFURAN-2-ONE DERIVATIVE AND PRODUCTION PROCESS THEREFOR | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2002-10-17 | — | — | US | disclosed |
| EP-1249448-A1 | 3-Acetyl-n-substituted-3-aminomethyltetrahydroguran-2-one derivative and process therefor | Daicel Chemical Industries, Ltd. (JP) | 2002-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151727-A1 | 3-ACETYL-N-SUBSTITUTED-3-AMINOMETHYLTETRAHYDROFURAN-2-ONE DERIVATIVE AND PRODUCTION PROCESS THEREFOR | FAR1, ALDH7A1, NAT1 | ALDH1A1 20/4885CYP2C9 707/4885LMNA 3256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.